The Multinational Association of Supportive Care in Cancer (MASCC) was founded in 1991, and joined forces with the International Society of Oral Oncology (ISOO) in 1998. The "mission" of MASCC is to optimize supportive care in cancer patients worldwide, stimulate multi-disciplinary research, encourage international scientific exchange of information, expand professional expertise in supportive care, educate health care professionals worldwide in supportive care, and to serve as a resource for patients, families, and caregivers. Ten years ago, the most frequently addressed supportive care symptoms included pain, febrile neutropenia, and the prevention of nausea and vomiting. These topics are still indeed relevant for cancer patients, but today focus has also turned to topics such as mucositis, and specific supportive care problems in the elderly. Recent, studies have indicated that individually targeted supportive care therapy might become an important part of clinical practice in the near future.
In 1993 supportive care was defined as: "The comprehensive medical, nursing and psychosocial help that the patients need besides specific therapy of cancer" (1) . This definition has recently been modified to emphasize the continuum of support that is often necessary whether the patient is cured or eventually dies from the cancer disease. The definition is today: "Supportive care is the prevention and management of the adverse effects of cancer and its treatment. This includes physical and psychosocial symptoms and side effects across the entire continuum of the cancer experience including the enhancement of rehabilitation and survivorship" (2).
The "mission" of MASCC is to optimize supportive care in cancer patients worldwide, stimulate multi-disciplinary research, encourage international scientific exchange of information, expand professional expertise in supportive care, educate health care professionals worldwide in supportive care, and to serve as a resource for patients, families, and caregivers. Today, approximately 60% of cancer patients survive more than 5 years from the time of diagnosis. The effects of cancer itself and the chronic toxicity from cancer therapy can adversely affect patients' physical, psychological and social function (3), emphasizing the need for research in rehabilitation of cancer patients (rehabilitation phase). In Table 1 , a list of supportive care problems is given.
Ten years ago, the most frequently addressed supportive care symptoms included pain, febrile neutropenia, and the prevention of nausea and vomiting. These areas of supportive care have developed differently. Pain research has primarily focused on new administration forms of well-known drugs and different pain syndromes including breakthrough pain (4), but still many patients are inadequately treated. The development in the management of febrile neutropenia has focused on new antibiotics but also on more simple schedules going from combination antibiotic therapy to monotherapy, and from inpatient therapy to outpa- In the past few years new areas of supportive care have emerged. The alliance between MASCC and ISOO has resulted in highly effective integration of science used in the investigation of mucositis and in the development of evidence-based guidelines (7) . Also supportive care in the elderly has become a major focus area. The elderly population increases and it has for years been recognized, that elderly patients with cancer deserve special attention, whether they receive therapy with curative intent or they need palliative therapy for terminal cancer (8) .
Pharmacogenetic research has led to the development of individually targeted therapy for some cancer diseases. E.g. the understanding that a single factor, such as mutations in the tyrosine kinase moiety of the epidermal growth factor, is responsible for tumor growth, has led to the development of drugs like imatinib (chronic myeloid leukemia and gastrointestinal stromal tumors) and gefitinib (lung cancer). The recognition that variations in the metabolic pathways of cytotoxins and supportive care drugs (e.g., antiemetics) are clinically relevant, has led to the exploration of molecular targets for the improvement of symptom management. Innocenti and coworkers recently published a trial investigating the significance of genetic variants in the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene. They showed that variation in this gene predicted the risk of severe neutropenia after treatment with irinotecan, a drug using UGT1A1 in its metabolic pathway (9) . The importance of the cytochrome P-450 enzyme system has also been verified in the antiemetic setting.
Competition for the same metabolic pathways and gene variations can in theory lead to either rapid metabolism, and thereby a decrease in the effect of an antiemetic, or to poor metabolism, resulting in increased toxicity. Kaiser et al. investigated 270 patients receiving chemotherapy and antiemetic therapy with a 5-HT3 receptor antagonist (tropisetron or ondansetron) known to be metabolized through the CYP2D6 isoenzyme (10). They genotyped the patients and showed that genetically defined ultrarapid metabolizers had a higher frequency of vomiting than all other patients. They concluded that antiemetic therapy with a 5-HT3 receptor antagonist could be improved by adjustment for the CYP2D6 genotype.
In the future, when genotyping methods become cheaper and consequently generally available, individually targeted supportive care therapy will probably become an important part of clinical practice.
